NASDAQ$SIGA

SIGA Technologies, Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

SIGA Technologies' financial performance for Q2 2022 reflected increased revenues and profitability.

SIGA Technologies reported a strong second quarter in 2022, marked by increased revenues driven by initial sales of oral TPOXX to the Asia-Pacific region and the U.S. Department of Defense, alongside ongoing international orders.

  • Total revenue increased to $16.7 million compared to $8.7 million in Q2 2021.
  • Operating income reached $3.1 million, a significant improvement from $0.0 million in Q2 2021.
  • Net income was reported at $2.0 million, up from $0.2 million in the same quarter last year.
  • Diluted income per share stood at $0.03, compared to $0.00 in Q2 2021.

Headline financials

Total Revenue

$16.7M

Previous: $8.65M+92.6%
EPS (adj)

$0.03

Previous: $0.00+1257.5%
Capital Expenditures

$0.00

Previous: -$24.4K+100.0%
Free Cash Flow

$2.04M

Previous: $145K+1307.0%
Net Income

$2.04M

Previous: $169K+1103.9%
Operating Income

$3.07M

Previous: $1.1K+278548.9%
Gross Profit

$15.8M

Previous: $7.66M+106.1%
Cash & Equivalents

$115M

Previous: $98.5M+16.3%
Total Assets

$160M

Previous: $134M+19.6%
Stock-Based Comp

$395K

No prior period

Revenue & EPS history

SIGA Technologies · Revenue · Quarterly

$16.7M

Q2 2022+92.6%vs Q2 2021
Beat estimate in 0 of 3 quarters(0%)
ActualEstimate

Revenue by segment

SIGA Technologies · $16.7M total across 2 segments · Q2 2022

  • Product Sales
    $8.62M+24.4%
  • R&D Revenues
    $8.05M+365.6%

Forward guidance

SIGA Technologies anticipates a positive trend in the second half of 2022, driven by international orders for oral TPOXX, with deliveries expected through July 2023. The company expects $26 million of the $60 million in orders to be delivered in Q3 2022.

Tailwinds

  • Continued expansion and diversification of its revenue base.
  • Increase in the number of international governments procuring oral TPOXX.
  • Large number of inquiries regarding TPOXX procurement.
  • U.K. approval of oral tecovirimat for treatment of orthopoxviruses.
  • FDA approval of the intravenous formulation of TPOXX (IV TPOXX).

Headwinds

  • Potential risks associated with BARDA contracts, including possible modifications or cancellations.
  • Uncertainty in the development of the international biodefense market.
  • Risks related to the efficacy and safety of potential products in clinical trials.
  • Possible disruptions to SIGA’s supply chain for TPOXX manufacture.
  • Risks associated with responding to the current monkeypox outbreak.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

-0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+2.4%

Avg return

30 days after

41%

26 / 64 earnings

Positive

+31.9%

Q4 2023

Best reaction

-27.8%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.4%-5.5%-8.5%
Q4 2025-3.0%-3.4%-22.8%
Q3 2025-20.2%-24.0%-24.1%
Q1 2025+4.4%+9.0%+10.8%
Q4 2024+7.0%+0.5%+6.4%
Q3 2024-1.9%-8.5%-9.8%
Q2 2024-12.8%-14.3%-9.5%
Q1 2024-27.8%-28.2%-26.7%
Q4 2023+31.9%+49.9%+88.3%
Q3 2023-4.4%-2.2%+16.9%
Q2 2023-3.7%-10.0%-21.9%
Q1 2023+5.1%+1.8%-0.7%
Q4 2022-3.8%-7.8%-13.4%
Q3 2022+7.5%+9.8%+1.1%
Q2 2022+27.4%+24.6%-21.0%
Q1 2022+3.6%+4.0%+60.7%
Q4 2021+3.0%+6.6%+22.4%
Q3 2021-0.7%+0.0%+2.8%
Q2 2021-2.9%-4.0%+9.1%
Q1 2021-0.7%-8.4%-10.4%
Q4 2020+1.7%+9.3%+1.2%
Q3 2020+2.0%+3.4%-0.9%
Q2 2020+14.3%+5.5%-1.9%
Q1 2020-1.4%+1.4%+2.9%
Q4 2019+10.4%+0.4%+0.2%
Q3 2019-3.2%-1.8%-19.8%
Q2 2019+0.2%-1.7%+2.7%
Q1 2019+1.5%-1.3%-12.8%
Q4 2018-4.4%-1.6%-6.3%
Q3 2018+8.4%+5.7%+29.1%
Q2 2018+0.3%+7.7%+1.4%
Q1 2018-0.5%+2.4%-3.9%
Q4 2017-0.6%-7.0%-2.3%
Q3 2017+2.8%-1.1%+3.9%
Q2 2017-1.6%-1.6%-1.9%
Q1 2017-0.3%+0.6%-8.0%
Q4 2016-0.6%+0.0%-4.1%
Q3 2016-5.7%+3.8%+54.8%
Q2 2016+4.5%+4.1%+11.4%
Q1 2016+1.1%
Q4 2015+1.1%
Q3 2015+2.4%
Q2 2015-0.9%
Q1 2015+5.7%
Q4 2014-1.3%
Q3 2014-0.7%
Q2 2014-4.9%
Q1 2014-1.4%
Q4 2013-2.7%
Q3 2013-3.5%
Q2 2013-2.8%
Q1 2011-2.4%
Q4 2012-2.5%
Q3 2012+6.5%
Q2 2012+5.3%
Q1 2012+4.5%
Q4 2011-1.4%
Q4 2009-1.4%
Q3 2010-6.1%
Q3 2011-6.1%
Q2 2011-12.0%
Q2 2010-12.0%
Q4 2010-12.0%
Q1 2010-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro